Pulse Biosciences Inc
Change company Symbol lookup
Select an option...
PLSE Pulse Biosciences Inc
ENBL Enable Midstream Partners LP
SPVU Invesco S&P 500® Enhanced Value ETF
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
SPG Simon Property Group Inc
SPFF Global X SuperIncome™ Preferred ETF
SPDV AAM S&P 500 High Dividend Value ETF
SOXS Direxion Daily Semiconductor Bear 3X Shares
SOXL Direxion Daily Semiconductor Bull 3X Shares
SOLOW Electrameccanica Vehicles Corp *W EXP 08/13/2023

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Pfizer's stock surges toward biggest post-earnings gain in over 9 years

3:11 pm ET July 28, 2020 (MarketWatch)

Shares of Pfizer Inc. (PFE) surged 4.6% in afternoon trading Tuesday, to pace the Dow Jones Industrial Average's (PFE) gainers, after the drug maker reported second-quarter results (http://www.marketwatch.com/story/pfizers-stock-surges-after-profit-and-revenue-beats-raised-guidance-2020-07-28) that beat expectations and raised its financial guidance. The stock is currently on track to post the best one-day post-earnings gain since it shot up 5.5% on Feb. 1, 2011, after Pfizer reported fourth-quarter 2010 results (http://www.marketwatch.com/story/pfizers-profit-gets-a-boost-from-tax-gain-2011-02-01). On the day of the past 20 quarterly reports, Pfizer's stock has gained eight times, with an average gain of 2.8%, according to an analysis of FactSet data. After the other 12 earnings reports, the average decline was 1.9%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 28, 2020 15:11 ET (19:11 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.